Mutations present at the time of diagnosis. Shown are all mutations present at the time of AML diagnosis in the 295 patients in the cohort. Every patient is represented in an individual column, whereas genes and other AML features are listed in rows. Mutations are sorted by molecular ontogeny,⁴ with TP53 mutations listed first in green, secondary-type mutations (implying evolution from an antecedent MDS) in blue, and all other mutations (pan-AML/de novo type) below. NPM1 mutations and internal tandem duplications in FLT3 (FLT3-ITD) are in red, and DDX41 mutations are in gold. Complex cytogenetics are shown (top) above the TP53 mutations. The proportion of patients in the cohort with each alteration is reported on the right.